Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523937 | 0.89 | HPGD (0.64) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4525757 | 0.88 | RAB9A (0.60) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4519586 | 0.88 | HPGD (0.56) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4522870 | 0.84 | HPGD (0.67) | HPGDGRM5NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4560091 | 0.83 | HPGD (0.66) | HPGDGRM5NPC1RAB9AALDH1A1 | |
| SCHEMBL4520206 | 0.83 | HPGD (0.58) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4521372 | 0.83 | HPGD (0.68) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4520705 | 0.81 | HPGD (0.62) | HPGDNPC1RAB9AALDH1A1PROKR1 | |
| SCHEMBL4530457 | 0.80 | HPGD (0.67) | HPGDNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4527873 | 0.79 | HPGD (0.97) | HPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-19 | — | — | US | claimed |
| EP-1960373-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-27 | — | — | EP | claimed |
| WO-2007060144-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-31 | — | — | WO | claimed |
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| EP-1960373-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060144-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | GRM2, GRIK5, GRIN2A | HPGD 470/4885GRM5 8/4885NPC1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.